Estimation of Total Immunity to SARS-CoV-2 in Texas

DeSantis, Stacia M.; Leon‐Novelo, Luis; Swartz, Michael D.; Yaseen, Ashraf; Valerio, Melissa A.; Brito, Frances A.; Ross, J. Andrew; Kohl, Harold W.; Messiah, Sarah E.; Kelder, Steve; Wu, Leqing; Zhang, Shiming; Aguillard, Kimberly; Gonzalez, Michael O.; Omega-Njemnob, Onyinye S.; Breaux, Camille; Lakey, David; Shuford, Jennifer A.; Pont, Stephen J.; Boerwinkle, Eric

doi:10.1101/2021.08.05.21261610

Cited by 2 publications

(1 citation statement)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Texas Coronavirus Antibody REsponse Survey (Texas CARES) is an ongoing prospective population-based seroprevalence project designed to assess antibody status over time among a volunteer population throughout the state. The design of Texas CARES has been described previously 2,3,4 but briefly, includes adults (aged 20-80 years) and children (aged 5-19 years).…”

Section: Methodsmentioning

confidence: 99%

Durability of SARS-CoV-2 Antibodies from Natural Infection in Children and Adolescents

Messiah¹,

Brito

Kohl

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

BackgroundRecent data suggest the SARS-CoV-2 Delta (B.1.617.2) variant is more transmissible among children compared to the Alpha (B.1.1.7) variant. The true incidence and longitudinal presence of antibody response to SARS-CoV-2 infection is not known, however. We provided estimates of antibody response using Texas Coronavirus Antibody REsponse Survey (Texas CARES) data, a prospective population-based seroprevalence project designed to assess antibody status over time among the general population throughout the state.MethodsIn October 2020 Texas CARES began enrolling adults (aged 20-80 years) and children (aged 5-19 years). Participants were offered a series of three SARS-CoV-2 antibody tests over 6-8 months, or every 2-3 months that includes the immunoassay for detection of antibodies to the SARS-CoV-2 nucleocapsid protein (Roche N-test). Descriptive characteristics and COVID-19 infection-related symptom status was determined by questionnaire at the time of enrollment and prior to each successive blood draw. This analysis included participants ages 5-to-19 years old who have completed all three antibody assessments.ResultsFrom our sample (n=159; mean age 12.5 years, SD 3.6), 96% of those with evidence of nucleocapsid antibodies at baseline assessment continued to have antibodies > six months later (mean 7.0 months, SD 0.97). There was no difference in the presence of antibodies by symptom status (asymptotic versus symptomatic) or severity (mild-moderate versus severe), sex, age group, or body mass index group (underweight, healthy weight, overweight, obesity) over the three antibody measurement timepoints.ConclusionsThese results suggest that infection-induced antibodies persist and thus may provide some protection against future infection for at least half a year. 57.9% of the sample were negative for infection-induced antibodies at their third measurement point, suggesting a significant proportion of children have still not acquired natural infection.

show abstract

Section: Methodsmentioning

confidence: 99%

Durability of SARS-CoV-2 Antibodies from Natural Infection in Children and Adolescents

Messiah¹,

Brito

Kohl

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

Combined Impact of Prior SARS-CoV-2 Infection and Vaccination on Antibody Presence

Boerwinkle

Shuford

Swartz³

et al. 2021

Preprint

View full text Add to dashboard Cite

As COVID-19 continues to spread rapidly and vaccine uptake stagnates, questions remain about the amount of SARS-CoV-2 antibodies present in the population induced by either SARS-CoV-2 infection, by a COVID-19 vaccine, or both. The TEXAS Coronavirus Antibody REsponse Survey (CARES) is a statewide seroprevalence program which utilizes the Roche S-test to detect antibodies to the SARS-CoV-2 spike protein and the Roche N-test to detect antibodies to the SARS-CoV-2 nucleocapsid protein, to monitor the combined impact of prior infection and the COVID-19 vaccine. The current sample size having both S- and N-test data and reported vaccination status is 8,846. Participants with prior infection (i.e. N+) and with either partial or full vaccination have the highest proportion of those showing the maximum value of the S-test (80.95% and 83.07%, respectively). Using a permutation test, there is no statistically significant difference between the median S-test value for those that have had prior infection and are partially vaccinated versus those that have had prior infection and are fully vaccinated. These groups both show significantly higher median amount compared to the other three groups: N+/not vaccinated, N-/partially vaccinated, and N-/fully vaccinated (all p-values < 0.0001). Unvaccinated individuals with prior infection have one of the lowest median S-test values. For participants with previous SARS-CoV-2 infection and a COVID-19 vaccine, the median S-test value is high and is not statistically different between those who are partially vaccinated and those who are fully vaccinated.

show abstract

Estimation of Total Immunity to SARS-CoV-2 in Texas

Cited by 2 publications

References 28 publications

Durability of SARS-CoV-2 Antibodies from Natural Infection in Children and Adolescents

Durability of SARS-CoV-2 Antibodies from Natural Infection in Children and Adolescents

Combined Impact of Prior SARS-CoV-2 Infection and Vaccination on Antibody Presence

Contact Info

Product

Resources

About